Oxford Gene Technology expands NGS custom cancer panel content

Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content. The expansion comes in response to increasing use of NGS as a tool for research into an increasing number of cancer types allowing researchers to obtain reliable data for difficult-to-sequence genes and mutations.

This content is optimised for haematology and solid tumours including breast, colorectal, lung, ovarian and prostate cancer, glioma, melanoma, sarcoma, leukaemia’s, myeloproliferative neoplasms and myelodysplastic syndrome.

Dr Anna Skowronska, research and development scientist at West Midlands Regional Genetics Laboratory, has been using the SureSeq Myeloid Panel content. Skowronska commented: ‘We’ve found that the SureSeq Panel performs very well and has detected all known positives with an excellent variant detection of around 1 per cent. We were positively surprised right from the very first analysis by the level of mutation detection achievable.'

Targeted gene panels apply next-generation sequencing (NGS) technology to interrogate the mutations of multiple genomic regions of interest simultaneously. The specific panels can include regions of the genome that are associated with a disease or phenotype of interest. Gene panels can help researchers discover point mutations, insertions/deletions, copy number variations and translocations that could be missed with traditional sequencing techniques.

OGT closely collaborates with leading experts and examines the current literature to provide the most up-to-date targeting of all relevant regions. This includes exonic, intronic and splice sites, and delivers comprehensive insight into disease-driving mutations.

Dave Cook, senior product manager at OGT stated that OGT are working continually to improve results and ensure that they provide the most recent and relevant content. Cook stated: ‘Our coverage and reproducibility is unrivalled in the market and we wanted to expand the accessibility of quality NGS data to a wider range of cancer types—including genes and regions that are known to be difficult to sequence. We’re committed to helping customers reach their goals and we’re pleased to report that our expertise has enabled us to overcome these sequencing difficulties, giving them more confidence in the data they are generating.’

Twitter icon
Google icon icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon

Robert Roe explores efforts to diversify the HPC processor market


Darren Barrington-Light, senior manager product marketing for Thermo Fisher Scientific, explains the importance of integrating LIMS into the pharmaceutical data chain


Gemma Church looks at the use of additive manufacturing processes in engineering